EUCTR2016-001432-35-ES进行中（未招募）1 期
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355) - A Phase III Study of Chemotherapy ± Pembrolizumab in 1L Triple Negative Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 858
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have signed informed consent to study participation. The subject may also provide consent for Future Biomedical Research (FBR). However, the subject may participate in the main trial without participating in FBR.
- •2. Be at least 18 years of age on the day of signing informed consent.
- •3. Have locally recurrent inoperable breast cancer not previously treated with
- •chemotherapy and which cannot be treated with curative intent.
- •Have metastatic breast cancer not previously treated with chemotherapy.
- •Note: Subjects with a history of locally recurrent breast cancer, which was previously treated with curative intent, may be eligible.
- •4. Have centrally confirmed TNBC, as defined by the most recent ASCO/CAP
- •guidelines.
- •Note: Subjects initially diagnosed with hormone receptor–positive and/or
- •HER2-positive breast cancer must have central confirmation of TNBC in a tumor
- •biopsy obtained from a local recurrence or distant metastasis site.
- •5. Have completed treatment for Stage I-III breast cancer, if indicated, and =6 months elapsed between the completion of treatment with curative intent (e.g., date of primary breast tumor surgery or date of last adjuvant chemotherapy administration, whichever occurred last) and first documented local or distant disease recurrence.
- •Note: First documentation of local or distant disease recurrence must be in the form of a dated biopsy, pathology, or imaging study report. A laboratory report indicating tumor marker elevation cannot be used as documentation of local or distant disease recurrence, unless accompanied by dated biopsy, pathology, or imaging study report.
- •Note: Subjects who received taxane, gemcitabine, or platinum agents in the
- •(neo)adjuvant setting can be treated with same class of chemotherapy (taxane or gemcitabine/carboplatin), if =12 months have elapsed between the completion of treatment with curative intent (e.g., date of primary breast tumor surgery or date of last adjuvant chemotherapy administration, whichever occurred last) and first documented local or distant disease recurrence.
- •6. Have been treated with (neo)adjuvant anthracycline, if they received systemic
- •treatment in the (neo)adjuvant setting, unless anthracycline was contraindicated or not considered the best treatment option for the subject in the opinion of the treating physician.
- •Note: Subjects presenting with de novo metastatic TNBC are eligible for the study, if anthracycline is contraindicated or not considered the best treatment option for the subject in the opinion of the treating physician.
- •7. Have measurable disease based on RECIST 1.1 as determined by local radiology review.
- •Note: Target lesions situated in a previously irradiated area are considered
- •measurable, only if they have shown unequivocal progression based on RECIST 1.1 after radiation therapy.
- •Note: Chest wall recurrence can be used as a target lesion, only if measurable by
- •diagnostic quality imaging modality (digital photography alone is not adequate).
- •8. Have provided recently or newly obtained core or excisional biopsy from a locally recurrent inoperable or metastatic tumor lesion for central determination of TNBC status and PD-L1 expression, unless contraindicated due to site inaccessibility and/or subject safety concerns.
- •Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory. Submission of another tumor specimen may be required, if adequate tumor tissue was not provided the first time.
- •Note: An archival tumor speci
排除标准
- •1.Is currently participating in a clinical study and receiving an investigational agent and/or using an investigational device, or has participated in a clinical study and received an investigational agent and/or used an investigational device within 4 weeks prior to randomization.
- •Note: Subjects who have entered the follow-up phase of a clinical study may participate as long as 4 weeks have elapsed since the last dose of the investigational agent and/or removal of the device.
- •2.Has not recovered (e.g., to =Grade 1 or to baseline) from AEs due to a previously administered therapy.
- •Note: Alopecia of any grade is an exception to this criterion.
- •Note: Prior to randomization, the subject must have recovered adequately from any toxicity and/or complications associated with any recent procedure.
- •3.Has neuropathy =Grade 2.
- •4.Has an active autoimmune disease that has required systemic treatment in the past 2 years (e.g., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
- •5.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.
- •6.Has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, and in situ cervical cancer.
- •7.Has known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they have stable brain metastases and did not receive chemotherapy for metastatic breast cancer.
- •Note: Known brain metastases are considered active, if any of the following criteria are applicable:
- •a. Brain imaging during screening demonstrates progression of existing metastases and/or appearance of new lesions compared to brain imaging performed at least 4 weeks earlier.
- •Radiographic stability of previously treated brain metastases is based on local radiology/investigator review, but dated reports of 2 imaging studies (the most recent performed during screening) documenting stability of brain metastasis(es) over =4 weeks must be submitted to the Sponsor. Such brain imaging studies should be available at the site for submission to CIV, if later needed.
- •b.Neurological symptoms attributed to brain metastases have not returned to baseline
- •c.Steroids were used for management of symptoms related to brain metastases within 28 days of randomization
- •8.Has active, or a history of, pneumonitis requiring treatment with steroids.
- •9. Has active, or a history of, interstitial lung disease.
- •10. Has a known history of active TB (Bacillus Tuberculosis)
- •11. Has an active infection requiring systemic therapy.
- •12. Has a history of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization.
- •13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject participation for the full duration of the study, or render study participation not compatible with the subject’s best interest, in the opinion of the treating Investigator.
- •14. Has a known psychiatric or substance abuse disorder
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast CancerHigh-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast CancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2017-004869-27-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,140
进行中（未招募）
1 期
A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast CancerHigh-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast CancerMedDRA version: 21.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864EUCTR2017-004869-27-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,140
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerTriple-Negative Breast CancerEUCTR2016-001432-35-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerTriple-Negative Breast CancerEUCTR2016-001432-35-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858
已完成
3 期
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer * (KEYNOTE-355)Breast cancerNL-OMON47725Merck Sharp & Dohme (MSD)12